Clinical Trials Logo

Filter by:
NCT ID: NCT05597969 Completed - Adult Clinical Trials

The Effect of an Application-based Health Intervention (FoodCoach) on Food Purchases in Switzerland

Start date: November 9, 2022
Phase: N/A
Study type: Interventional

The FoodCoach study is a 9-week randomized controlled trial from the University of St.Gallen and the University Hospital of Bern, supported by the Swiss National Science Foundation #188402 and by Sanitas Management AG. Sanitas Management AG supports the recruiting of study participants without interfering with the study content. FoodCoach aims to investigate the effectiveness of improving people's food shopping healthiness by providing automated food shopping recommendations. The results of the study could possibly help improve the health status of the Swiss population and beyond in a low-cost and automated manner. The investigators collect participant grocery data via the loyalty card programs "Migros Cumulus" and "Coop Supercard" after obtaining participants' informed consent. From this data, the investigators generate automated recommendations that are based on the Nutri-Score framework and expertise of dieticians at the University Hospital of Bern. After sign-up, participants are randomized into a treatment and a control group. The treatment group receives automated recommendations via the FoodCoach Web Application, while the control group only receives a report about their food shopping by email after the intervention phase. Both groups need to finish the same onboarding survey where the investigators collect basic demographic information. After the intervention, the treatment group will receive a post-study survey containing two parts via email. Part 1 includes questions about the ease of use, interface and satisfaction and usefulness of the FoodCoach app. Part 2 includes questions about the participants' weight and height, the motivation to shop healthily and sustainably. The control group will receive a post-study survey which only contains part 2 as described before via email.

NCT ID: NCT05593874 Completed - Diabetic Foot Clinical Trials

Predictive Value of Nu.Q™ Biomarkers to Help Guiding the Management of Osteoarticular Infections

Start date: October 10, 2022
Phase:
Study type: Observational [Patient Registry]

Diabetic foot ulcers are frequent with average lifetime risk of 15%, and can lead to bone and joint infections. Current protocols for their management include evaluation of ischemia, assessment of underlying bone infection, sharp debridement, off-loading and use of dressings that promote moist wound healing. Extensive debridement is optimal for wound healing and decreases the risk of recurrence. However, extension of surgical debridement is left at the clinician judgement and thus lacks standardised protocols. Plus, there is currently no known risk factors or specific biomarkers that can help guide the clinician for the extent of debridement or that can predict a recurrence in case of non-extensive debridement. The main objectives of the study are to either unravel a new biomarker, and/or identify risk factors associated with poor prognosis following surgical debridement in diabetic foot ulcers. Histones, more specifically H3.1 subtype, have been associated with sepsis. The main hypothesis is that higher blood levels of H3.1 will be present in participants showing poor prognosis (i.e., having additional surgeries, amputation, death) and that a rise in H3.1 blood levels compared to baseline (before the 1st surgical intervention) would provide an early warning of relapse or treatment failure.

NCT ID: NCT05585515 Completed - Sleep Deprivation Clinical Trials

Metabolomics-based Sleepiness Markers

ME-SMART
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Estimating that people sleep on average up to two hours less over the last decades, sleepiness and fatigue need to be considered as significant societal problems of the modern world. Jurisdiction is precise on how to deal with overtired offenders since they were not allowed to use machines or vehicles in the first place, similar to drunk individuals or consumers of illicit drugs. In contrast to alcohol or illicit drug use, however, there are no quick roadside or workplace tests as objective (analytical) biomarkers for sleepiness. Investigators hypothesize that increasing sleep drive or impaired wakefulness can be assessed by qualitative or quantitative fluctuations of certain metabolites in biological specimens, e.g., accumulation or decrease of endogenous substances related to sleep debt. Thus, this sleep study provides the necessary biological samples of either sleep-deprived, sleep-restricted, or control subjects, which are then analysed for appropriate metabolite biomarkers utilizing an untargeted metabolomics approach. In addition to established impairment tests, a state of the art driving simulator will be employed to objectively measure driving performance under all study conditions. Participants will also rate their subjective sleepiness using validated questionnaires.

NCT ID: NCT05580783 Completed - Iron-deficiency Clinical Trials

Iron Absorption and Variations of Iron Status, Hepcidin, Inflammation and Sex Hormones During the Menstrual Cycle

MBL_Abs
Start date: November 5, 2022
Phase: N/A
Study type: Interventional

Iron supplementation is the first line of treatment of iron deficiency in most women, but we do not know when the best time is to supplement in the context of the menstrual cycle. With this study, we aim to measure and compare iron status, hepcidin, inflammatory markers, hormones estrogen and progesterone and changes in iron absorption at various points throughout the menstrual cycle, with a long-term view to determine best time for iron supplementation in relation to the menstrual cycle.

NCT ID: NCT05575843 Completed - Clinical trials for Multiple Sclerosis (MS)

Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®

SMARTCARE
Start date: December 9, 2022
Phase: N/A
Study type: Interventional

The Expanded Disability Status Scale (EDSS) is the gold-standard in assessing disability in Multiple Sclerosis (MS). Its current digital form, the Neurostatus-eEDSS®, often serves as primary endpoint in MS clinical trials. The pandemic revealed the need for telemedical alternatives to the in-clinic assessment. Therefore, Neurostatus-SMARTCARE was developed: A trained and certified non-neurologist Health Care Professional (HCP) examines the patient while the examination is being video-recorded. The stored video allows a neurologist to re-assess the examination at a later point of time. The future application could be in-home visits through HCPs, in decentralized clinical trials as well as in routine care. In this study, the concordance rate of Neurostatus examinations between neurologists and HCPs is investigated. With a concordance rate significantly higher than 80%, Neurostatus-SMARTCARE by HCPs can be considered equal to the standard Neurostatus-EDSS by neurologists.

NCT ID: NCT05569876 Completed - Diabetes Mellitus Clinical Trials

The HypoVoice Study

HypoVoice
Start date: November 11, 2022
Phase: N/A
Study type: Interventional

The HypoVoice study aims at identifying potential vocal biomarkers associated with hypoglycemia to pave the way towards a voice-based hypoglycemia detection approach.

NCT ID: NCT05561712 Completed - NAD Clinical Trials

Method Optimization for the Quantification of the NAD

Start date: February 25, 2022
Phase:
Study type: Observational

Method optimization for the quantification of the NAD metabolome in human whole blood, and evaluation of baseline inter and intra-subject variability.

NCT ID: NCT05561621 Completed - Multiple Sclerosis Clinical Trials

Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers

COMMITMENT
Start date: July 15, 2022
Phase:
Study type: Observational

The investigator will set up a study evaluating vocal biomarkers in people with MS in order to identify persons with non-motor symptoms: depression, cognitive deterioration, and fatigue. Up to now, to the best of the investigator's knowledge, there is no study reporting the use of vocal biomarkers to predict these three non-motor symptoms in people with MS.

NCT ID: NCT05559034 Completed - Mental Fatigue Clinical Trials

Brain Oxygenation Marker for Cognitive Function in Healthy Adults

Start date: September 6, 2022
Phase:
Study type: Observational [Patient Registry]

This study aims to identify a cortical oxygenation marker for cognitive function using functional Near Infrared Spectroscopy in healthy adults.

NCT ID: NCT05557422 Completed - Clinical trials for Chronic Lymphoproliferative Diseases (CLPD)

BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System.

Start date: October 12, 2022
Phase:
Study type: Observational

Multi-site, prospective performance study to determine equivalency between the investigational CLPD Full Panel on the FACSLyric system versus the final clinical diagnosis.